Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits.
Bleomycin is the antineoplastic agent used most commonly for the treatment of malignant pleural effusion. It is absorbed rapidly from the pleural space and does not elicit pleurodesis in the normal rabbit pleura. Mitoxantrone is a new antineoplastic that differs from bleomycin in that it binds to membranes. Accordingly it might remain in the pleural space for a longer period and produce a pleurodesis. The objective of this project was to determine whether mitoxantrone is an effective sclerosant in an experimental model in rabbits. The following medications were instilled intrapleurally in anesthetized male rabbits: 35 mg/kg tetracycline or 0.5, 1.0, or 2.0 mg/kg mitoxantrone. The animals were killed at 28 days and the pleural spaces assessed grossly for pleurodesis and microscopically for fibrosis and inflammation. The mean degree of gross pleurodesis did not differ significantly in the rabbits that received tetracycline (3.8 +/- 0.4) and in the rabbits that received 2 mg/kg mitoxantrone (3.2 +/- 1.3). The degree of pleural and lung inflammation was significantly greater after mitoxantrone than after tetracycline, both ipsilaterally and contralaterally. The mortality after the highest dose of mitoxantrone was 50%. From this study we conclude that the intrapleural administration of mitoxantrone in rabbits can produce a pleurodesis. The histologic picture after mitoxantrone administration differs markedly from that after tetracycline injection. After mitoxantrone injection there are many more inflammatory cells present on the side that received the injection, and there is much more fibrosis and inflammation in the contralateral pleura and lung. The model of pleural fibrosis following intrapleural mitoxantrone may be useful for the study of pleural fibrosis.
Department of Medicine of the Veterans Administration Medical Center Long Beach, California 90822, USA.
R W
RW
Light
N S
NS
Wang
J A
JA
Despars
S E
SE
Gruer
C
C
Sassoon
F S
FS
Vargas
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D005355:Fibrosis / Q000473:pathology; D007928:Lethal Dose 50; D008297:Male; D008942:Mitoxantrone / Q000494:pharmacology* / Q000633:toxicity; D010994:Pleura / Q000187:drug effects* / Q000473:pathology; D018700:Pleurodesis; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D012597:Sclerosing Solutions / Q000494:pharmacology*; D013752:Tetracycline / Q000494:pharmacology* / Q000633:toxicity
D000970:Antineoplastic Agents; D011500:Protein Synthesis Inhibitors; D012597:Sclerosing Solutions; D008942:Mitoxantrone; D013752:Tetracycline